News

Patients with intermediate-2 or high-risk primary or secondary MF were involed in open label, randomised dose-ranging study that assessed the once-daily oral doses of 300mg, 400mg, and 500mg

The trial focuses on Reparixin’s oral administration in combination with paclitaxel in women with metastatic breast cancer. The completed second cohort, in which patients were not limited to

Paracetamol is an over the counter analgesic drug. The company has submitted the product to the FDB labs for testing and is yet to receive final approval, which

COTI will look after the discovery, profiling and optimization activities of the drug candidates. Under the two step approach, COTI will identify and deliver early set of compounds

The new facility will provide the additional space needed for Impact Analytical as well as safe, efficient and accurate analysis of customer samples. Impact Analytical business manager Eric

OMS824 was well tolerated in the SAD study in which expected pharmacological effects were established in healthy subjects. The trial was designed to assess the multiple-dose administration of

Under the collaboration, Lilly will in-license a portfolio of branded generic injectable and oral cancer medicines from Agila Specialties, the specialties division of Strides Arcolab based in Bangalore,

The annual general meeting held on 17 October 2012, has approved the acquisition of 100% of the shares of X-Pol by way of a capital increase against contribution

The drug developed by Sol-Gel, is used to treat mild-to-severe rosacea as well as acne. The study demonstrated that 5% E-BPO provides a safe and effective treatment for